[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356670-105":59,"doc-detail-356670-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-cross-scale-multimodal-framework-identifies-clinically-actionable-immunotherapy-biomarkers-in-melanoma-research-open-access","A cross-scale multimodal framework identifies clinically actionable immunotherapy biomarkers in melanoma - RESEARCH Open Access","","Melanoma, a skin cancer that can metastasize, still lacks highly precise individualized treatment options. A cross-scale multimodal strategy integrates bulk to single-cell and spatial transcriptomics to derive melanoma molecular subtypes and immunotherapy-relevant signatures. Multi-omics results are validated across independent cohorts, supported by TWAS using GTEx and UK Biobank, and further refined through machine-learning signatures and tumor microenvironment analyses. Single-cell and spatial data clarify pathomechanisms and therapeutic target candidates.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-cross-scale-multimodal-framework-identifies-clinically-actionable-immunotherapy-biomarkers-in-melanoma-research-open-access/356670/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-cross-scale-multimodal-framework-identifies-clinically-actionable-immunotherapy-biomarkers-in-melanoma-research-open-access/356670.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this study address in melanoma treatment?","Question",{"text":112,"@type":113},"Melanoma currently lacks highly precise individualized treatment options, and many patients receive limited benefit from immunotherapy. The study aims to identify biomarkers and signatures that improve clinical actionability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were molecular subtypes identified and validated?",{"text":117,"@type":113},"The authors performed multi-omics integration on the TCGA-SKCM cohort to identify melanoma molecular subtypes, then validated identified genes in independent GEO meta-cohorts. They further used TWAS validation with GTEx and UK Biobank datasets.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the key findings from the tumor microenvironment and prognostic model analyses?",{"text":121,"@type":113},"Two molecular subtypes (CS1 and CS2) were found, with CS2 showing better prognosis and enrichment in immunesuppressive pathways and CS1 showing higher PI3K activation, DNA repair mechanisms, and invasiveness. A CMLS prognostic model stratified patients into high- and low-risk groups using six significant prognostic-related genes, and single-cell/spatial analyses highlighted distinct microenvironment interactions and progression trajectories.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356670,1790393386,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Huoshen et al. Human Genomics (2026) 20:77 Human Genomics  \n[https://doi.org/10.1186/s40246-026-00919-w](https://doi.org/10.1186/s40246-026-00919-w)  \nRESEARCH Open Access  \nA cross-scale multimodal framework identifies   clinically actionable immunotherapy biomarkers in melanoma through bulk to single-cell and spatial transcriptomics integration  \nWuda Huoshen1,2†, Kun Yuan3†, Junkai Xiong2†, Yilong Lin4,5†, Wenjie Yu6,7,8, Yun Xie9, Qian Yuan10, Xinyue Zhang11, Changqing Dong12, Chen Sun13* and Sha Yi1*  \nAbstract  \nBackground Melanoma, a type of skin cancer that can spread to other parts of the body, currently lacks highly precise individualized treatment options.  \nMethods We performed multi-omics integration on The Cancer Genome Atlas Skin Cutaneous Melanoma (TCGASKCM) cohort to identify melanoma molecular subtypes. The identified genes were validated in independent meta cohorts from GEO, followed by transcriptome-wide association study (TWAS) validation using Genotype-Tissue Expression (GTEx) and UK Biobank datasets. Additionally, we analyzed machine learning-driven signature (CMLS) development, tumor microenvironment characteristics, immunotherapy response, and potential therapeutic targets. Finally, single-cell and spatial transcriptomics provided further biological insights and the pathomechanisms.  \nResult Our study identified two distinct molecular subtypes of SKCM using multimodal data integration with the MOVICS package: Cancer Subtype 1 (CS1) and CS2 . CS2 showed a better prognosis and was enriched in immunesuppressive pathways such as WNT–β signaling, while CS1 exhibited higher activation of the PI3K pathway and DNA repair mechanisms, along with greater tumor invasiveness. TWAS analysis results combined the findings from TCGASKCM and the meta-cohort, identifying six significant prognostic-related genes (SPRGs) . The CMLS prognostic model, based on SPRGs (CAP2, SELL, and LAPTM5 as risk factors and GZMA, FCER1G, and LYZ as protective factors), stratified patients into high-group (poorer survival) and low-risk groups. Single-cell and spatial transcriptomic analyses further  \n†Wuda Huoshen, Kun Yuan, Junkai Xiong andYilong Lin have contributed equally to this work.  \n*Correspondence:  \nChen Sun [sunchen0711@hotmail.com](sunchen0711@hotmail.com)[ ](sunchen0711@hotmail.com)Sha Yi [yisha890124@163.com](yisha890124@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nHuoshen et al. Human Genomics (2026) 20:77 Page 2 of 24  \nvalidated CMLS prognostic results, highlighting distinct tumor microenvironment interactions and progression trajectories.  \nConclusion Identifications of molecular subtypes and CMLS represent a valuable tool for early prediction of patient prognosis and for screening potential candidates likely to benefit from immunotherapy, with broad implications for clinical practice foundation for personalized therapies.  \nKeywords Cutaneous melanoma, Multi-omics, Prognostic model, Single-cell transcriptomics, Spatial transcripto","cbCaikcltpD3Qp52","https://ap.wps.com/l/cbCaikcltpD3Qp52","pdf",17718771,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Disease overview and epidemiology\n## Current management and immunotherapy challenges","[{\"question\":\"What problem does this study address in melanoma treatment?\",\"answer\":\"Melanoma currently lacks highly precise individualized treatment options, and many patients receive limited benefit from immunotherapy. The study aims to identify biomarkers and signatures that improve clinical actionability.\"},{\"question\":\"How were molecular subtypes identified and validated?\",\"answer\":\"The authors performed multi-omics integration on the TCGA-SKCM cohort to identify melanoma molecular subtypes, then validated identified genes in independent GEO meta-cohorts. They further used TWAS validation with GTEx and UK Biobank datasets.\"},{\"question\":\"What are the key findings from the tumor microenvironment and prognostic model analyses?\",\"answer\":\"Two molecular subtypes (CS1 and CS2) were found, with CS2 showing better prognosis and enrichment in immunesuppressive pathways and CS1 showing higher PI3K activation, DNA repair mechanisms, and invasiveness. A CMLS prognostic model stratified patients into high- and low-risk groups using six significant prognostic-related genes, and single-cell/spatial analyses highlighted distinct microenvironment interactions and progression trajectories.\"}]","A cross-scale multimodal framework identifies clinically actionable immunotherapy biomarkers in melanoma - RESEARCH Open Access | PDF",1790126741,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f919393834fd4cc5d6d2fd7cde51e59d.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/260768761c9440d353d2fc921cfb724b.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7204a5bf84fa5f6c4e681d1c86fb221.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/703acbd0c617ebc3823aae1ae9343b76.webp",980,1306]